Novel Combination of Mesenchymal Stem Cell-Conditioned Medium with Sorafenib Have Synergistic Antitumor Effect of Hepatocellular Carcinoma Cells

OBJECTIVE: Hepatocellular carcinoma (HCC) is the most common liver malignancy. Sorafenib is the first-line systemic treatment for advanced HCCs. However, due to safety concerns, researchers are now looking for ways to boost the efficacy of the medication. One approach for reducing toxicity is combin...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Asian Pac J Cancer Prev
Päätekijät: Seyhoun, Iman, Hajighasemlou, Saieh, Ai, Jafar, Hosseinzadeh, Faezeh, Mirmoghtadaei, Milad, Seyhoun, Seyed Moein, Parseh, Benyamin, Abdolahi, Shahrokh, Ghazvinian, Zeinab, Shadnoush, Mahdi, Verdi, Javad
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: West Asia Organization for Cancer Prevention 2019
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6485565/
https://ncbi.nlm.nih.gov/pubmed/30678447
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.31557/APJCP.2019.20.1.263
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia